More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$170.97B
EPS
4.86
P/E ratio
48.2
Price to sales
6.82
Dividend yield
0.529%
Beta
0.898722
Previous close
$234.33
Today's open
$235.34
Day's range
$234.29 - $242.22
52 week range
$171 - $258.23
show more
CEO
Rainer M. Blair
Employees
63000
Headquarters
Washington, DC
Exchange
New York Stock Exchange
Shares outstanding
706349563
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • 21 hours ago

Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Seeking Alpha • Jan 13, 2026

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors
Mar Vista's U.S. Quality strategy returned +0.20% net-of-fees in Q4 2025. The Russell 1000 Index and the S&P 500 Index returned +2.41% and +2.65%, respectively. Alphabet, Johnson & Johnson and Danaher Corp. were among the portfolio's top contributors for the quarter.
Seeking Alpha • Jan 13, 2026

Danaher CEO to Comment on Financial Performance
WASHINGTON, Jan. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2025 performance in a presentation at the J.P.
PRNewsWire • Jan 12, 2026

The Lab Equipment Titan Trading at Half the Multiple Just Delivered Another Beat
Danaher (NYSE: DHR) and Thermo Fisher Scientific (NYSE: TMO) both reported Q3 2025 earnings showing revenue growth around 5%, but underlying business momentum tells very different stories.
24/7 Wall Street • Jan 10, 2026

Danaher Is Ready to Put Its Post-Covid Malaise Behind It
With tariff rules finalized and inventories depleted, there's light at the end of the tunnel for the medical and scientific tools manufacturer.
Barrons • Jan 8, 2026

The Big 3: BA, DHR, DG
Dan Deming offers a glimpse into companies outside the AI trade he sees rallying in 2026. He offers bullish perspective and example options trades for Boeing (BA), Danaher (DHR), and Dollar General (DG).

Danaher to Present at J.P. Morgan Healthcare Conference
WASHINGTON, Jan. 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
PRNewsWire • Jan 5, 2026

Top 15 High-Growth Dividend Stocks For January 2026
My Top 15 High-Growth Dividend Stock list delivered a 0.83% gain in December, outperforming SPY and VIG. The Value-tilted portfolio variant led with a 2.17% December return, suggesting undervaluation may drive near-term alpha. Collectively, the January 2026 list offers a 1.35% yield, 16.87% five-year dividend growth, and appears 29% undervalued.
Seeking Alpha • Jan 3, 2026

The Value Traps Of The REIT Sector
A low valuation is not enough in the REIT sector. Many of the cheapest REITs are also the worst investments. I highlight many REIT value traps to avoid going into 2026.
Seeking Alpha • Dec 27, 2025

¹ Disclosures

Open an M1 investment account to buy and sell Danaher Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.